University of Pittsburgh Medical Center’s investment and innovation arm has allocated $1bn to drug development funding over the next four years.
UPMC Enterprises, the investment and innovation arm of healthcare provider University of Pittsburgh Medical Center (UPMC), announced on Tuesday it plans to invest $1bn in the development of drugs, diagnostics and devices by 2024.
The figure includes a $200m partnership with University of Pittsburgh, announced in early 2018, to establish the Immune Transplant and Therapy Center. The hub will focus on the development of immunotherapies for a wide range of diseases.
UPMC is closely affiliated with University of Pittsburgh’s Schools…
